This invention involved a new methodology using novel targets, TMS stimulation and a hypnosis protocol to modulate traits and help chronic pain, addiction, and mental disorders.
Researchers in the laboratories of Prof. Stanley Cohen and Prof Tzu-Hao Cheng have discovered that Supt4h is a potential therapeutic target for reducing toxicity and restoring the functionality of deleterious proteins in Huntington's (HD) and other polyQ diseases.
Dr. Stanley Cohen and colleagues have identified small molecular compounds that may be useful in the treatment of nucleotide repeat diseases. A well-known nucleotide repeat disorder is Huntington's disease.
Researchers in Prof. Karl Deisseroth's laboratory have developed a novel system for modulating brain activity with moderate intensity focused ultrasound. In this technique, ultrasound is used to increase the intrinsic firing rate of targeted neurons.
Researchers from Prof. Karl Deisseroth's laboratory have developed techniques for specifically modulating the activity of excitable cells in vivo. This approach introduces light-responsive proteins to create photo-sensitive cells.
The inventors have developed a light-driven chloride pump (NpHR or Halo) for temporally precise optical inhibition of neural activity with ordinary yellow light.
Temporally precise, noninvasive control of neural circuitry is a long-sought goal of neuroscientists and biomedical engineers. Stanford University researchers in the laboratory of Dr.
Researchers in the laboratories of Dr. Karl Deisseroth and Dr. Peter Hegemann have engineered mutant ChR2 (Channelrhodopsin-2) proteins with light-sensitivity that is increased by orders of magnitude compared to wild-type ChR2.
Researchers in Prof. Karl Deisseroth's lab have discovered and engineered new microbial opsin proteins and cell trafficking tools to enable selective cell-type specific, light-sensitive switches for neuromodulation.